BMS stakes $80m on Prothena's neurodegenerative candidate [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Prothena Corporation plc - Ordinary Shares (PRTA)
Last prothena corporation plc - ordinary shares earnings: 2/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.prothena.com
Company Research
Source: Yahoo! Finance
The deal for the asset also includes an additional $617.5m in additional development, regulatory, and sales milestone-related payments, as well as royalties, as per a 28 May press release by Prothena. The two companies have neither disclosed the modality of PRX019 nor the intended indication within the neurodegenerative disease space. The US Food and Drug Administration (FDA) greenlit the drug for use in clinical trials in December 2023, with Ireland-based Prothena saying it now plans to initiate a Phase I clinical trial with the drug by the end of this year. BMS' Neuroscience Thematic Research Center head Richard Hargreaves said: “Through our partnership with Prothena, we have identified and advanced PRX019 as a potential disease-modifying treatment option for patients suffering from neurodegenerative diseases.” Hargreaves said that asset adds to BMS' “growing neuroscience pipeline.” The licence deal for PRX019 is not the first time BMS and Prothena have worked together. B
Show less
Read more
Impact Snapshot
Event Time:
PRTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRTA alerts
High impacting Prothena Corporation plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRTA
News
- ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal [Yahoo! Finance]Yahoo! Finance
- Prothena to Participate in Upcoming Healthcare ConferencesBusiness Wire
- A New Era For Alzheimer's Disease May Be Around The Corner [Forbes]Forbes
- What Makes Prothena (PRTA) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks [Yahoo! Finance]Yahoo! Finance
PRTA
Earnings
- 8/8/24 - Beat
PRTA
Sec Filings
- 8/8/24 - Form S-8
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- PRTA's page on the SEC website